【作者】 柴洁；

【导师】 马学真；

【作者基本信息】 青岛大学 ， 肿瘤学， 2012， 硕士

【摘要】 目的探讨乳腺癌组织中多药耐药指标P-糖蛋白(P170)、胚胎性谷胱甘肽-S-转移酶-π(GST-π)和DNA拓扑异构酶Ⅱ(TOPOⅡ)与人表皮生长因子受体2(HER-2)基因表达的相关性及临床意义。方法乳腺癌组织48例。采用荧光原位杂交法(Fluorescence in situ hybridization, FISH)检测HER-2基因的表达；采用免疫组化法(Immunohistochemistry, IHC)检测已知HER-2基因表达情况的乳腺癌病例标本中P170、GST-π和TOPOⅡ的表达情况；分析三者与临床病理因素(年龄、原发肿瘤大小、有无淋巴结转移)的关系及与HER-2基因的相关性。应用SPSS13.0统计学软件行X~2检验及Spearman相关性检验,显著性检验水准α=0.05(双侧)。结果48例乳腺癌中HER-2基因表达者阳性为22例(45.8%)。P170、GST-π、TOPOⅡ阳性表达率分别为43.8%(21/48)、39.6%(19/48)、56.3%(27/48)。P170、GST-π、TOPOⅡ表达与年龄、原发肿瘤大小、淋巴结转移无关(P>0.05)。P170、GST-π、TOPO表达率在HER-2阳性病例中明显高于HER-2阴性的病例(P<0.05)。P170、GST-π、TOPO表达与HER-2基因表达存在相关性(P<0.05)。结论P170、GST-π、TOPOⅡ表达与HER-2呈正相关,均可作为临床上检测及指导治疗的重要指标。更多还原

【Abstract】 Objective To investigate the correlation between the expression of P170, GST-π, TOTOII and the expression of HER-2in human breast cancer.Methods The expression of HER-2was detected by fluorescence in situ hybridization. The expression of P170, GST-π, TOTOII were tested in48cases breast cancer by immunohistochemical method, and their correlations with clinicopathological feathers and the expression of HER-2were analyzed.Results The positive rate of P170, GST-π, TOTOII were43.8%,39.6%,56.3%respectively. The expression of P170, GST-π, TOTOII positively correlated with the expression of HER-2(P<0.05). The levels of P170, GST-π, TOTOII expression were not associated with age, primary tumor and lymph node metastasis(P>0.05).Conclusion There was great possibility of chemotherapy drug resistance in breast cancer with expression of HER-2. Expressions of P170, GST-π, TOTOII and HER-2have an instructive significance for chemotherapy.更多还原